Veracyte (VCYT) Cost of Revenue (2012 - 2026)

Veracyte has reported Cost of Revenue for 15 years, with the latest figure at $36.3 million in Q2 2026.

• Cost of Revenue for Q2 2026 came in at $36.3 million, up 12.04% year-over-year; the trailing twelve-month figure through Jun 2026 was $136.5 million (up 12.5% YoY), and the FY2025 annual result was $127.6 million, up 11.34% from the prior year.
• Cost of Revenue advanced to $36.3 million in Q2 2026, from $33.3 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $36.3 million in Q2 2026 and troughed at $17.5 million in Q1 2022.
• A 5-year average of $26.4 million and a median of $26.9 million in 2024 frame the typical range for Cost of Revenue.
• The widest annual swing landed in 2022, when Cost of Revenue soared 61.77%; it then grew 4.65% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $19.4 million in 2022, then rose by 24.29% to $24.1 million in 2023, then soared by 31.28% to $31.6 million in 2024, then advanced by 4.65% to $33.1 million in 2025, then advanced by 9.64% to $36.3 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $36.3 million in Q2 2026, $33.3 million in Q1 2026, and $33.1 million in Q4 2025.